Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Aegerion cuts jobs as Juxtapid competition grows

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) said it will cut costs and reduce global staff by 25% as its hypercholesterolemia treatment Juxtapid lomitapide faces increased competition.The company said in January it …

    Published on 2/11/2016
  • COMPANY NEWS: EMA to review Sandoz Neulasta biosimilar

    The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said EMA accepted an MAA for LA-EP2006, its proposed biosimilar of Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN), to treat chemotherapy-induced neutropenia. In …

    Published on 2/11/2016
  • COMPANY NEWS: FDA schedules meeting to review Intercept's OCA

    FDA's Gastrointestinal Drugs Advisory Committee will meet on April 7 to discuss an NDA from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) for obeticholic acid (DSP-1747) to treat primary biliary cholangitis (PBC).The …

    Published on 2/11/2016
  • COMPANY NEWS: Shire focusing on integration in near term

    Shire plc (LSE:SHP; NASDAQ:SHPG) CEO Flemming Ornskov said the company is on track to complete its acquisition of Baxalta Inc. (NYSE:BXLT) mid-year, and plans to focus in the near term on integration of Baxalta and …

    Published on 2/11/2016
  • COMPANY NEWS: Grail hires ex-Google exec Huber as CEO

    Cancer diagnostics company Grail Bio (Redwood City, Calif.) named Jeff Huber CEO and said GV invested in its series A round. Huber previously focused on data-driven life sciences projects as an SVP at the Google[X] …

    Published on 2/10/2016
  • COMPANY NEWS: Mylan acquiring Meda

    Generics company Mylan N.V. (NASDAQ:MYL) will acquire Meda AB (SSE:MEDAA) for about SEK83.6 billion ($9.9 billion) in cash and stock, or SEK60.3 billion ($7.1 billion) net of debt. Meda makes specialty pharma products, …

    Published on 2/10/2016
  • COMPANY NEWS: Priority Review for KemPharm's pain candidate

    KemPharm Inc. (NASDAQ:KMPH) gained $2.16 (21%) to $12.67 on Wednesday after FDA granted Priority Review to an NDA for KP201/APAP for short-term management of acute pain. Its PDUFA date is June 9.The NDA is Kempharm's …

    Published on 2/10/2016
  • COMPANY NEWS: Synlogic unveils AbbVie deal in IBD

    Synthetic biology company Synlogic Inc. (Cambridge, Mass.) revealed Wednesday that AbbVie Inc. (NYSE:ABBV) is its partner in a deal to develop engineered bacteria as an oral therapeutic for inflammatory bowel disease (…

    Published on 2/10/2016
  • COMPANY NEWS: Management tracks

    Immunology company Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) hired James Bucher as SVP and general counsel. Bucher was VP of corporate legal affairs and corporate compliance officer at Exelixis Inc. (NASDAQ:EXEL).…

    Published on 2/9/2016
  • COMPANY NEWS: Cigna, Novartis strike outcomes-based Entresto deal

    Cigna Corp. (NYSE:CI) said Monday that it struck an outcomes-based pricing deal with Novartis AG (NYSE:NVS; SIX:NOVN) for heart failure drug Entresto sacubitril/valsartan.Cigna said the agreement ties financial terms to…

    Published on 2/8/2016
  • COMPANY NEWS: Management tracks

    Protein degradation newco C4 Therapeutics Inc. (Cambridge, Mass.) hired Andrew Phillips as CSO. He was senior director of the center for development of therapeutics at the Broad Institute of MIT and Harvard.Achillion …

    Published on 2/8/2016
  • COMPANY NEWS: NICE rebuffs Praluent, reverses course on Repatha

    The U.K.'s NICE issued draft guidance recommending against the use of Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) alone or in combination with lipid-…

    Published on 2/8/2016
  • COMPANY NEWS: Pfizer unveils post-merger management team

    Pfizer Inc. (NYSE:PFE) named the management team that is to lead the company after it completes its merger with Allergan plc (NYSE:AGN).Pfizer intends to combine its Global Innovative Pharma (GIP) and Vaccines, Oncology…

    Published on 2/8/2016
  • COMPANY NEWS: FDA issues CRL for Kalydeco

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) fell $5.11 to $86.61 on Friday after FDA issued a complete response letter for an sNDA seeking to expand the label of cystic fibrosis drug Kalydeco ivacaftor to include patients…

    Published on 2/5/2016
  • COMPANY NEWS: Gilead's Mansuri joining Sanofi

    Sanofi (Euronext:SAN; NYSE:SNY) hired Muzammil Mansuri as EVP of strategy and business development, effective Feb. 22. In the role, he also will be responsible for the pharma's Sanofi-Genzyme BioVentures corporate …

    Published on 2/5/2016
  • COMPANY NEWS: SciClone seeking alternatives

    SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) gained $0.65 to $8.76 on Friday after reporting late Thursday that it settled an investigation with the SEC and hired Lazard to help the company seek strategic alternatives. …

    Published on 2/5/2016
  • COMPANY NEWS: FDA panel backs cognitive dysfunction claim for Brintellix

    FDA's Psychopharmacologic Drugs Advisory Committee voted 8-2 on Wednesday that H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) provided substantial evidence to support an efficacy claim…

    Published on 2/4/2016
  • COMPANY NEWS: Tessier-Lavigne to become Stanford president

    Stanford University (Stanford, Calif.) hired Marc Tessier-Lavigne as president, effective Sept. 1. He will succeed John Hennessy, who last year announced plans to step down as president.Tessier-Lavigne has been …

    Published on 2/4/2016
  • COMPANY NEWS: Mersana, Takeda expand relationship

    Mersana Therapeutics Inc. (Cambridge, Mass.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) rights to co-develop Mersana's lead internal program, XMT-1522, a preclinical antibody-drug conjugate (ADC) targeting HER2…

    Published on 2/3/2016
  • COMPANY NEWS: Adaptimmune, GSK expand TCR deal for NY-ESO-1

    Adaptimmune Therapeutics plc (NASDAQ:ADAP) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expanded a deal under which the companies are co-developing an autologous T cell receptor (TCR) therapy targeting cancer/testis …

    Published on 2/2/2016
  • COMPANY NEWS: Gilead still eyeing cancer, inflammation deals

    Gilead Sciences Inc. (NASDAQ:GILD) reported earnings that showed a continued reliance on HCV sales and company executives expressed interest in dealmaking to broaden Gilead's cancer and inflammatory portfolios."It's …

    Published on 2/2/2016
  • COMPANY NEWS: U.K. court invalidates Regeneron mouse patents

    Kymab Ltd. (Cambridge, U.K.) said the English High Court revoked two patents from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) protecting VelocImmune mice and humanized mouse antibodies derived from the mice. Regeneron …

    Published on 2/2/2016
  • COMPANY NEWS: Abbott buys diagnostics company Alere

    Abbott Laboratories (NYSE:ABT) is acquiring diagnostics play Alere Inc. (NYSE:ALR) for $56 per share in cash, or about $5.8 billion. Abbott said it will assume or refinance Alere's net debt of $2.6 billion. The …

    Published on 2/1/2016
  • COMPANY NEWS: Avalanche acquires Annapurna

    Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 …

    Published on 2/1/2016
  • COMPANY NEWS: Huya, Eisai strike deal for Chipscreen drug

    Huya Bioscience International LLC (San Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000 in several Asian territories. Huya has ex-China rights to the drug from Shenzhen Chipscreen …

    Published on 2/1/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993